TrialPloS one2019

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.

Yehuda Z Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.